Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dectaflur SCHEMBL19356830 | 0.84 | SLC6A5 (0.34) | TLR8 | |
| Dectaflur SCHEMBL19356580 | 0.83 | SLC6A5 (0.33) | — | |
| SCHEMBL15510966 | 0.78 | KCNH2 (0.35) | MEN1KMT2ATSHRTLR8 | |
| Methyl Alcohol SCHEMBL6497173 | 0.74 | STAT3 (0.39) | — | |
| Chloromethane SCHEMBL5164781 | 0.74 | STAT3 (0.39) | — | |
| SCHEMBL3846982 | 0.74 | STAT3 (0.41) | — | |
| SCHEMBL2032798 | 0.74 | STAT3 (0.41) | — | |
| Phosphine SCHEMBL1401296 | 0.74 | STAT3 (0.41) | — | |
| Iodide SCHEMBL6764783 | 0.74 | STAT3 (0.41) | — | |
| SCHEMBL6034867 | 0.74 | STAT3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401430-A4 | SUBSTITUTED PORPHYRIN AND AZAPORPHYRIN DERIVATIVES AND THEIR USE IN PHOTODYNAMIC THERAPY, RADIOIMAGING AND MRI DIAGNOSIS | MIRAVANT PHARM INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050226810-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | MIRAVANT PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
| US-6906050-B2 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | MIRAVANT PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1401430-A1 | SUBSTITUTED PORPHYRIN AND AZAPORPHYRIN DERIVATIVES AND THEIR USE IN PHOTODYNAMIC THERAPY, RADIOIMAGING AND MRI DIAGNOSIS | Miravant Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030100752-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | MIRAVANT PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002096417-A1 | SUBSTITUTED PORPHYRIN AND AZAPORPHYRIN DERIVATIVES AND THEIR USE IN PHOTODYNAMIC THERAPY, RADIOIMAGING AND MRI DIAGNOSIS | MIRAVANT PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100752-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | PPOX, HMBS, MPI | DNM1 1964/4885MEN1 639/4885KMT2A 1758/4885 |
| US-20050226810-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | PPOX, HMBS, MPI | DNM1 2080/4885MEN1 157/4885KMT2A 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.